{"id":742820,"date":"2023-03-27T09:08:12","date_gmt":"2023-03-27T13:08:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/"},"modified":"2023-03-27T09:08:12","modified_gmt":"2023-03-27T13:08:12","slug":"aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/","title":{"rendered":"AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast"},"content":{"rendered":"
\n

OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) <\/strong>(\u201cAIM\u201d or the \u201cCompany\u201d), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases \u2014 including COVID-19, the disease caused by the SARS-CoV-2 virus \u2014 today announced that it will report its financial results for the full year December 31, 2022 after market close on Friday, March 31, 2023. AIM ImmunoTech management will host its inaugural quarterly conference call and live audio webcast to discuss the operational and financial results on Monday, April 3rd<\/sup> at 8:30 AM ET.<\/p>\n

The call will be hosted by members of AIM\u2019s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The live webcast<\/a> will be accessible on the Events and Presentations<\/a> page of the Investors section of the Company\u2019s website, aimimmuno.com<\/a>, and will be archived for 90 days following the live event.<\/p>\n

\n About AIM ImmunoTech Inc.<\/strong>\n <\/p>\n

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The Company\u2019s lead product, an investigational new drug called Ampligen\u00ae<\/sup> (rintatolimod) is an immuno-modulator with broad spectrum activity being investigated for globally important cancers, viral diseases and disorders of the immune system.<\/p>\n

For more information, please visit aimimmuno.com<\/a> and connect with the Company on Twitter<\/a>, LinkedIn<\/a>, and Facebook<\/a>.<\/p>\n


\n
\n \n <\/div>\n

\n
Investor Relations Contact\r\nJTC Team, LLC\r\nJenene Thomas\r\n833-475-8247\r\nAIM@jtcir.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (\u201cAIM\u201d or the \u201cCompany\u201d), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases \u2014 including COVID-19, the disease caused by the SARS-CoV-2 virus \u2014 today announced that it will report its financial results for the full year December 31, 2022 after market close on Friday, March 31, 2023. AIM ImmunoTech management will host its inaugural quarterly conference call and live audio webcast to discuss the operational and financial results on Monday, April 3rd at 8:30 AM ET. The call will be hosted by members of AIM\u2019s leadership team, Thomas K. Equels, Chief Executive … <\/p>\n
Continue reading “AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-742820","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (\u201cAIM\u201d or the \u201cCompany\u201d), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases \u2014 including COVID-19, the disease caused by the SARS-CoV-2 virus \u2014 today announced that it will report its financial results for the full year December 31, 2022 after market close on Friday, March 31, 2023. AIM ImmunoTech management will host its inaugural quarterly conference call and live audio webcast to discuss the operational and financial results on Monday, April 3rd at 8:30 AM ET. The call will be hosted by members of AIM\u2019s leadership team, Thomas K. Equels, Chief Executive … Continue reading "AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-27T13:08:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTIyNyM1NDgxMDk4IzIwMjMxNjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast\",\"datePublished\":\"2023-03-27T13:08:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\\\/\"},\"wordCount\":275,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NTIyNyM1NDgxMDk4IzIwMjMxNjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\\\/\",\"name\":\"AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NTIyNyM1NDgxMDk4IzIwMjMxNjQ=\",\"datePublished\":\"2023-03-27T13:08:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NTIyNyM1NDgxMDk4IzIwMjMxNjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NTIyNyM1NDgxMDk4IzIwMjMxNjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/","og_locale":"en_US","og_type":"article","og_title":"AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast - Market Newsdesk","og_description":"OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (\u201cAIM\u201d or the \u201cCompany\u201d), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases \u2014 including COVID-19, the disease caused by the SARS-CoV-2 virus \u2014 today announced that it will report its financial results for the full year December 31, 2022 after market close on Friday, March 31, 2023. AIM ImmunoTech management will host its inaugural quarterly conference call and live audio webcast to discuss the operational and financial results on Monday, April 3rd at 8:30 AM ET. The call will be hosted by members of AIM\u2019s leadership team, Thomas K. Equels, Chief Executive … Continue reading \"AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-27T13:08:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTIyNyM1NDgxMDk4IzIwMjMxNjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast","datePublished":"2023-03-27T13:08:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/"},"wordCount":275,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTIyNyM1NDgxMDk4IzIwMjMxNjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/","name":"AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTIyNyM1NDgxMDk4IzIwMjMxNjQ=","datePublished":"2023-03-27T13:08:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTIyNyM1NDgxMDk4IzIwMjMxNjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NTIyNyM1NDgxMDk4IzIwMjMxNjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-to-report-full-year-2022-financial-results-on-march-31-2023-and-host-inaugural-quarterly-conference-call-and-webcast\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=742820"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742820\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=742820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=742820"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=742820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}